Impact of bevacizumab on clinical outcomes and its comparison with standard chemotherapy in metastatic colorectal cancer patients: a systematic review and meta-analysis.

Tehnia NazAnees Ur RehmanAleena ShahzadMuhammad Fawad RasoolZikria SaleemRabia Hussain

Published in: Journal of pharmaceutical policy and practice (2024)

Our findings indicate that combining Bevacizumab with chemotherapy enhances clinical outcomes and results in a significant increase in PFS and OS in patients with metastatic colorectal cancer. Positive outcomes are demonstrated by a substantial 23% increase in PFS and 31% increase in OS in patients with metastatic colorectal cancer who undergo Bevacizumab in conjunction with chemotherapy

Keyphrases

metastatic colorectal cancer
locally advanced
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
squamous cell carcinoma
type diabetes
metabolic syndrome
patient reported outcomes
rectal cancer